Recent Updates
Recently added Catalysts
PODD Neutral Sentiment Score: 50/100

Insulet to Announce Second Quarter 2026 Financial Results on August 5, 2026

Key Takeaway: Insulet Corporation is set to announce its financial results for the second quarter of 2026 on August 5, 2026. This announcement is part of the company's regular financial reporting schedule. Investors and stakeholders are expected to review the results for insights into the company's performance.
Price reaction · baseline $152.25 (2026-06-30 close) · hit pre-market · 1 other PODD headline(s) in the window, move may be shared
day 0 close · peak
+5%

Market Sentiment Analysis

Full Press Release Details

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader intubeless insulin pump technologywith its Omnipod®brand of products, today announced it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time).
The link to the live call will be available on the Investor Relations section of the Company's website atinvestors.insulet.com, “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers; the passcode is 5904836.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit:Insulet.comoromnipod.com.
©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.
Last updated: Jul 1, 2026